Filana Therapeutics

FLNA · NASDAQ

$0.6885+$0.0065 (+0.95%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $0.682

About FLNA

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Employees: 17
Headquarters: Austin, Texas
Listed: Jul 14, 2000
Sector: Health Care
Industry: Pharmaceuticals
Website: cassavasciences.com

Leadership

Filana Therapeutics executives
Name	Title	Since	Age
Claude Nicaise	—	—	73
Richard Barry	—	2021	66
Eric Schoen	—	—	56
Angelique Bordey	—	—	—
Jack Moore	—	—	—
R. Christopher Cook	—	—	61
Freda Nassif	—	—	49
Robert Anderson	—	—	59
Dawn Bir	—	—	54
Pierre Gravier	—	—	40
Robert Gussin	—	—	87
Michael O'Donnell	—	—	66
Patrick Scannon	—	—	77

Similar companies

Companies in the same industry as Filana Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.